Gene-based therapy of malignant melanoma

Seminars in Oncology

Volumn 29, Issue 5, 2002, Pages 503-512

  Schadendorf, Dirk ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; B7 ANTIGEN; CHEMOKINE; CHIMERIC PROTEIN; CYTOKINE; DACARBAZINE; DNA VACCINE; GAMMA INTERFERON; GANCICLOVIR; GLYCOPROTEIN GP 100; IMMUNE PROTEIN 10; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 7; MACROPHAGE INHIBITORY PROTEIN; MELANOMA ANTIGEN; OBLIMERSEN; PEPTIDE MAGE 3; PEPTIDE MAGE A1; PEPTIDE MART 1; PROTEIN BCL 2; PROTEIN P53; RECOMBINANT VACCINE; T LYMPHOCYTE RECEPTOR; THYMIDINE KINASE; TRP2 DNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BLOOD TOXICITY; CANARYPOX VIRUS; CLINICAL TRIAL; DRUG SENSITIVITY; ERYTHEMA; FEVER; FLU LIKE SYNDROME; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VIVO STUDY; MELANOMA; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; PRURITUS; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SUICIDE GENE; T LYMPHOCYTE; TUMOR IMMUNITY; VERO CELL; VIRUS RECOMBINANT;

EID: 0037010051     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.35245     Document Type: Article

References (44)

1. Ahmann DL, Creagan ET, Hahn RG, et al: Complete responses and long-term survivals after systemic chemotherapy for patients with advanced melanoma. Cancer 63:224-227, 1989
2. Helmbach H, Rossmann E, Kern MA, Schadendorf D: Drug- resistance in human melanoma. Int J Cancer 93:617-622, 2001
3. Johnson TM, Smith JW, Nelson BR, et al: Current therapy for cutaneous melanoma. J Am Acad Dermatol 32:689-707, 1995
4. Dalgleish AG: Vaccine strategies for melanoma. Forum 5:375-393, 1995
5. Kirkwood JM: Studies of interferons in the therapy of melanoma. Semin Oncol 18:83-90, 1991
6. Oettgen HF, Old LJ: The history of cancer immunotherapy, in DeVita VT, Hellman S, Rosenberg SA (eds): The Biologic Therapy of Cancer: Principles and Practice. Philadelphia, PA, Lippincott, 1991, pp 87-119
7. Rosenberg SA, Lotze MT, Yang JC, et al: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474-485, 1989
8. Sun Y, Paschen A, Schadendorf D: Cell-based vaccination against melanoma-Background, preliminary results, and perspective. J Mol Med 77:593-608, 1999
9. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14:7-17, 1996
10. Tepper RI, Pattengale PK, Leder P: Murine interleukin-4 displays potent antitumor activity in vivo. Cell 57:503-512, 1989
11. Schadendorf D: Cytokines and cytokine-gene transfer in cancer treatment, in Burg G, Dummer R (eds): Strategies for Immunointervention in Dermatology. Heidelberg, Germany, Springer Verlag, 1997, pp 181-194
12. Parmiani G, Rodolfo M, Melani C: Immunological gene therapy with ex vivo gene-modified tumor cell critique and a reappraisal. Hum Gene Ther 11:1269-1275, 2000
13. Möller P, Sun Y, Dorbic T, et al: Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lyric activity in peripheral blood of patients with a good clinical performance status: A clinical phase I study. Br J Cancer 77:1907-1916, 1998
14. Sun Y, Jurgovsky K, Möller P, et al: Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical phase I study. Gene Ther 5:481-490, 1998
15. Möller P, Möller H, Sun Y, et al: Increased non-major histocompatibility complex-restricted lyric activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells. Cancer Gene Ther 7:976-984, 2000
16. Palmer K, Moore J, Everard M, et al: Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum Gene Ther 10:1261-1268, 1999
17. Schreiber S, Kampgen E, Wagner E, et al: Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study. Hum Gene Ther 10:983-993, 1999
18. Arienti F, Sule-Suso J, Belli F, et al: Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther 7:1955-1963, 1996
19. Belli F, Arienti F, Sule-Suso J, et al: Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability. Cancer Immunol Immunother 44:197-203, 1997
20. Arienti F, Belli F, Napolitano F, et al: Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum Gene Ther 10:2907-2916, 1999
21. Osanto S, Schiphorst PP, Weijl NI, et al: Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum Gene Ther 11:739-750, 2000
22. Veelken H, Mackensen A, Lahn M, et al: A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer 70:269-277, 1997
23. Mackensen A, Veelken H, Lahn M, et al: Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts. J Mol Med 75:290-296, 1997
24. Nawrocki S, Murawa P, Malicki J, et al: Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol Lett 15:81-86, 2000
25. Rochlitz C, Jantscheff P, Bongartz G, et al: Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors. Cancer Gene Ther 6:271-281, 1999
26. Tartour E, Mehtali M, Sastre-Garau X, et al: Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours Clinical and immunological findings. Br J Cancer 83:1454-1461, 2000
27. Sun WH, Burkholder JK, Sun J, et al: In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc Natl Acad Sci USA 92:2889-2893, 1995
28. + T-cell immunity. Cancer Gene Ther 5:321-330, 1998
29. Tartaglia J, Bonnet MC, Berinstein N, et al: Therapeutic vaccines against melanoma and colorectal cancer. Vaccine 19:2571-2575, 2001
30. Motta I, Andre F, Lim A, et al: Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. J Immunol 167:1795-1802, 2001
31. Chaux P, Luiten R, Demotte N, et al: Identification of five MACE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MACE-A1. J Immunol 163:2928-2936, 1999
32. Klatzmann D, Cherin P, Bensimon G, et al: A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Hum Gene Ther 9:2585-2594, 1998
33. Dummer R, Bergh J, Karlsson Y, et al; Biological activity and safety of adenoviral vector- expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors. Cancer Gene Ther 7:1069-1076, 2000
34. Jansen B, Schlagbauer-Wadl H, Brown BD, et al: bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4:232-234, 1998
35. Jansen B, Wacheck V, Heere-Ress E, et al: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356:1728-1733, 2000
36. Banerjee D: Genasense (Genta Inc) Curr Opin Invest Drugs 2:574-580, 2001
37. Zhai Y, Yang JC, Kawakami Y, et al: Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J Immunol 156:700-710, 1996
38. Mölling K, Strack B, Nawrath M, et al: Development of a DNA vaccine against malignant melanoma, in Burg G, Dummer RG (eds): Strategies for Immunointerventions in Dermatology. Berlin, Germany, Springer, 1997, pp 195-206
39. Schreurs MW, de Boer AJ, Figdor CG, et al: Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res 58:2509-2514, 1998
40. Wagner SN, Wagner C, Luhrs P, et al: Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo. J Invest Dermatol 115:1082-1087, 2000
41. Steitz J, Bruck J, Steinbrink K, et al: Genetic immunization of mice with human tyrosinase-related protein 2: Implications for the immunotherapy of melanoma. Int J Cancer 86:89-94, 2000
42. Mendiratta SK, Thai G, Eslahi NK, et al: Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer Res 61:859-863, 2001
43. Martin F, Neil S, Kupsch J, et al: Retrovirus targeting by tropism restriction to melanoma cells. J Virol 73:6923-6929, 1999
44. Willemsen RA, Weijtens ME, Ronteltap C, et al: Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther 7:1369-1377, 2000